Skip to content

Telotristat ethyl

Xermelo (telotristat ethyl) is a small molecule pharmaceutical. Telotristat ethyl was first approved as Xermelo on 2017-09-17. It is used to treat diarrhea and malignant carcinoid syndrome in the USA. It has been approved in Europe to treat carcinoid tumor and neuroendocrine tumors. It is known to target tryptophan 5-hydroxylase 1.
Trade Name Xermelo
Common Name Telotristat ethyl
Indication carcinoid tumor, diarrhea, malignant carcinoid syndrome, neuroendocrine tumors
Drug Class Enzyme inhibitors: tryptophan hydroxylase inhibitors
Telotristat ethyl
Get full access now